Teva Pharma (NYSE:TEVA) has been downgraded from Buy to Hold in a statement by Argus earlier today.
- Updated: March 19, 2017
Yesterday Teva Pharma (NYSE:TEVA) traded -0.85% lower at $35.75. Teva Pharma’s 50-day moving average is $34.27 and its 200-day moving average is $39.59. The last stock price is down -15.03% from the 200-day moving average, compared to the Standard & Poor's 500 Index which has increased 0.04% over the same time period. 4,486,627 shares of TEVA traded hands, down from an average trading volume of 10,457,500
Argus has downgraded Teva Pharma (NYSE:TEVA) from Buy to Hold in a report released on 2/28/2017.
Previously on 2/16/2017, Vetr Inc. reported about Teva Pharma (NYSE:TEVA) raised the target price from $0.00 to $40.48. At the time, this indicated a possible upside of 0.16%.
Recent Performance Chart
Teva Pharma has 52 week low of $31.90 and a 52 week high of $58.16 with a P/E ratio of 480.57 and has a market cap of $0.
In addition to Argus reporting its stock price target, a total of 22 brokers have issued a report on the company. The average stock price target is $72.82 with 10 brokers rating the stock a strong buy, 9 brokers rating the stock a buy, 6 brokers rating the stock a hold, 0 brokers rating the stock a underperform, and finally 0 brokers rating the stock a sell.
General Information About Teva Pharma (NYSE:TEVA)
Teva Pharmaceutical Industries Limited is a pharmaceutical company. The Company is engaged in developing, producing and marketing generic medicines and a portfolio of specialty medicines. The Company operates through two segments: Generic medicines and Specialty medicines. The Company develops, manufactures and sells generic medicines in a range of dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments and creams. Its specialty medicines business focuses on delivering a range of solutions to patients and providers through medicines, devices and services in various regions and markets around the world. Its specialty medicines business includes its core therapeutic areas of central nervous system (CNS) and respiratory medicines with a focus on asthma and chronic obstructive pulmonary disease. It also has specialty products in oncology, women's health and selected other areas.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.